Impact of Biphasic Cuirass Ventilation Compared to Non Invasive Ventilation in High Risk Extubations
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Jul 14, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to help people breathe after they are taken off a breathing machine (ventilator) in the hospital. The trial is looking at patients who are considered high risk for breathing problems once the ventilator is removed. Doctors usually use a method called Non-Invasive Ventilation (NIV), which means helping patients breathe using a mask without putting a tube down their throat. In this study, some patients will continue with the usual NIV care, while others will try a different method called Biphasic Cuirass Ventilation (BCV), which uses a special device placed on the chest to assist breathing.
To be part of this study, patients need to be adults between 18 and 80 years old who are in the intensive care unit and expected to need breathing support after coming off the ventilator. People who are pregnant, have certain chest problems, very high body weight, or specific muscle or nerve conditions won’t be able to join. If you take part, you will be randomly assigned to one of the two breathing support methods, and doctors will closely monitor how well each method works in helping you breathe after extubation. This study is not yet recruiting patients but aims to find out which breathing support method might be better for patients at high risk of breathing difficulties after ventilator use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • High risk extubation patients in the Medical Intensive care units who are being thought to be placed on non invasive ventilator post extubation.
- Exclusion Criteria:
- • Age \<18 or \>80
- • Pregnant
- • Inmate/Prisoner
- • Chest wall defects
- • BMI \>50
- • History of Diaphragmatic paralysis
- • History of Neuromuscular disease
- • Contraindication to study device (open chest wound, flail chest, complex thoracic surgeries in the past)
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Dennis B Chairman, MD
Principal Investigator
T
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported